Global Non-Alcoholic Steatohepatitis NASH Market

Global Non-Alcoholic Steatohepatitis NASH Market Opportunities And Strategies 2023

The Business Research Company’s global market reports are now updated with the latest market sizing information for the year 2023 and forecasted to 2032

The Business Research Company’s non-alcoholic steatohepatitis NASH market report forecasts the non-alcoholic steatohepatitis NASH market size to grow to $10.73 Billion by 2027, with a CAGR (compound annual growth rate) of more than 34%.

Learn More On The Non-Alcoholic Steatohepatitis NASH Market Report 2023 –

Non-Alcoholic Steatohepatitis NASH Market Size Forecast
The global non-alcoholic steatohepatitis NASH market is expected to grow from $2.42 billion in 2022 to $3.25 billion in 2023 at a compound annual growth rate (CAGR) of 34.5%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The non alcoholic steatohepatitis (NASH) market is expected to grow to $10.73 billion in 2027 at a CAGR of 34.7%.

North America held the largest non-alcoholic steatohepatitis NASH market share.

Key Non-Alcoholic Steatohepatitis NASH Market Driver ­– Rise In Cases Of Obesity
For example, according to the World Obesity Federation’s COVID-19 and Obesity: The 2021 Atlas, a report published in April 2021 by the World Obesity Federation, a UK-based federation that represents professional members of the scientific 2021, the percentage of overweight adults recorded more than 60% of the US population in April 2021; however, the obesity percentage of male expected to reach 44.2% and female 44.4% by 2025 in the US population. As a result, the rise in obesity cases will drive the growth of the Non-Alcoholic Steatohepatitis (NASH) market.

Request for A Sample Of The Global Non-Alcoholic Steatohepatitis NASH Market Report:

Key Non-Alcoholic Steatohepatitis NASH Market Trend – Technological Advancement
To remain competitive in the non-alcoholic steatohepatitis (NASH) market, major players are focusing on technological advancement. For example, in May 2021, GENFIT Inc., a biotechnology company based in France, launched NASHnext, a brand-new non-invasive test for diagnosing non-alcoholic steatohepatitis (NASH). NASHnext is powered by NIS4TM, a GENFIT-exclusive screening technology that uses a revolutionary blood-based molecular biomarker test to detect NASH and severe fibrosis. Labcorp, one of the world’s leading life sciences companies, is only making the test available in the United States and Canada.

Non-Alcoholic Steatohepatitis NASH Market Segment
1) By Type: Solid, Liquid
2) By Product: Vitamin E and Pioglitazone, Ocaliva, Elafibranor, Selonsertib and Cenicriviroc, Other Products
3) By Disease Cause: Hypertension, Heart Disease, High Blood Lipid, Type 2 Diabetes, Obesity
4) By Sales Channel: Hospital Pharmacy, Retail Pharmacy, Online Provider
5) By Application: Oral, Parenteral

Non-Alcoholic Steatohepatitis NASH Market Major Players and Strategies
Major players in the non-alcoholic steatohepatitis NASH market are AstraZeneca plc., Arena Pharmaceuticals Inc., GSK plc., Novo Nordisk A/S, F. Hoffmann-La Roche AG, Vivus LLC, Arisaph Pharmaceuticals Inc., Cempra Pharmaceuticals Inc., Galectin Therapeutics Inc., Galmed Pharmaceuticals Inc., Genfit SA, Gilead Sciences Inc., Immuron Limited, Raptor Pharmaceutical Inc., The Takeda Pharmaceutical Company Limited, Tobira Therapeutics Inc., VERVA Technologies Pvt. Ltd., Viking Therapeutics, Cadila Pharmaceuticals Ltd., Novartis AG, Conatus Pharmaceuticals Inc., One Way Liver S.L., and BioPredictive S.A.S.

Intercept Pharmaceuticals Inc was acquired for an undisclosed sum by Advanz Pharma Corp. Limited, a UK-based pharmaceutical company, in July 2022. Advanz Pharma hopes to establish a significant presence in the treatment of rare diseases with this agreement, which includes the ex-US rights to the orphan medicine Ocaliva (obeticholic acid), which is used to treat primary biliary cholangitis (PBC). Intercept Pharmaceuticals Inc is a biopharmaceutical company based in the United States that develops and markets innovative therapies for the treatment of progressive non-viral liver disorders.

The Non-Alcoholic Steatohepatitis NASH Global Market Report 2023 covers regional data on non-alcoholic steatohepatitis NASH market size, non-alcoholic steatohepatitis NASH market trends and drivers, opportunities, strategies, and non-alcoholic steatohepatitis NASH market competitor analysis. The countries covered in the non-alcoholic steatohepatitis NASH market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA, and the major seven regions are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa.

Non-alcoholic steatohepatitis (NASH) is a severe form of fatty liver disease characterised by inflammation of the liver and can progress to cirrhosis and liver failure.

View More Reports Related To The Non-Alcoholic Steatohepatitis NASH Market –
Alcoholic – Beverages Global Market Report 2023
Non Alcoholic – Beverages Global Market Report 2023
Organic Grain Farming Global Market Report 2023

Contact us at:
The Business Research Company:
+1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]

Follow us on:
Global Market Model:
Found this article helpful? Share it on: